After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Extra-cutaneous symptoms that suggest systemic ... The patient is a 47-year-old male with a 6-year history of systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome.

Deucravacitinib inhibits tyrosine kinase 2, which is implicated in cutaneous lupus erythematosus’s pathophysiology. Deucravacitinib yielded improvements in disease severity by week 16.

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.

and cutaneous lupus erythematosus, which affects the skin and has a broad spectrum of clinical manifestations. The treatment of SLE is highly individualized and physicians (mainly rheumatologists ...

In a small phase II trial of cutaneous lupus erythematosus (CLE), patients treated with the TYK2 inhibitor had as much as 50% improvement in disease status at week 16. Adverse events in both ...

Litifilimab, an anti-BDCA2 antibody, is being evaluated in Phase III trials for both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Biogen will use the funds to ...

The foregoing results lead to the conclusion that patients with disseminated lupus erythematosus and some patients with rheumatoid arthritis present a delayed cutaneous hypersensitivity when ...

Lupus Alert Day serves a vital purpose. It encourages others to learn more about lupus, share information on social media, ...

standard therapy alone, according to data. ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter ...

Key points A 47-year-old French-speaking woman of African descent presented to the emergency department with a 1-week history of severe foot pain and difficulty walking. For the preceding 2 months she ...